Related Experiment Video
Updated: Dec 16, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir
Alex E Rock1, Patricia L DeMarais2, Pamala T Vergara-Rodriguez2
1Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA. arock3674@gmail.com.
Abstract:
A potential drug-drug interaction exists between divalent and trivalent cations (Ca2+, Fe3+, Mg2+, Al3+, Zn2+) and HIV-1 integrase strand transfer inhibitors (INSTIs). There are limited case reports describing the clinical significance of this potential interaction and none to our knowledge identifying zinc co-administration with INSTIs. In this report we present a patient taking bictegravir/emtricitabine/tenofovir alafenamide who became viremic after ingesting zinc and calcium supplements and later was able to obtain virologic re-suppression after discontinuing supplements. This case represents a potential significant drug interaction between a commonly prescribed antiretroviral drug class and readily available over-the-counter divalent cation products.
Related Concept Videos
Retrovirus Life Cycles
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Retroviruses
Size and Structure of Viral Genomes
Subviral Agents

